Lacticaseibacillus paracasei YIT 9029 Enhances TCR Clone Repertoire
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The relationship between the intestinal environment and the number of T cell antigen receptor (TCR) clones after vaccination remains unclear, necessitating research on enhancers that can effectively enhance TCR clones.
Innovation Solution
Live lactic acid bacteria from the genus Lacticaseibacillus, particularly Lacticaseibacillus paracasei YIT 9029, are used as an active ingredient to enhance the number of TCR clones carrying TRBV19 and other specific V gene fragments, such as TRBV6-2, TRBV9, TRBV10-3, and TRBV12-4, after vaccination with viruses like influenza and COVID-19.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If conventional vaccination methods are used, then immune response is generated, but the number of TCR clones is insufficient for optimal immune protection
Solution Approach 1:
The patent applies preliminary action by administering live lactic acid bacteria (probiotics) before vaccination to pre-condition the intestinal environment and immune system. This preparatory step increases the number of TCR clones in advance, ensuring enhanced immune response when the vaccine is subsequently administered, thereby resolving the contradiction between TCR clone quantity and immune protection efficacy.
Solution Approach 2:
The patent uses live lactic acid bacteria as an intermediary substance that mediates between the vaccine and the immune system. These bacteria act as a bridge that enhances TCR clone expansion and improves the overall immune response to vaccination, addressing the insufficiency of TCR clones while maintaining reliable immune protection.
2Quantity of substance
If the intestinal environment is not adjusted, then vaccination can be administered, but TCR clone expansion is limited
Solution Approach 1:
The patent applies parameter changes by modifying the intestinal environment through the introduction of live lactic acid bacteria. This changes key parameters of the gut microbiota composition and immune system state, creating optimal conditions for TCR clone expansion after vaccination, thereby resolving the contradiction between TCR clone quantity and intestinal environment adaptability.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The use of live Lacticaseibacillus paracasei YIT 9029 significantly increases the number of TCR clones carrying TRBV19 and other specified V gene fragments, enhancing the TCR repertoire and providing improved immune recognition and protection against viruses.
Implementation Method 1
live lactic acid bacteria belonging to the genus Lacticaseibacillus as an active ingredient, wherein after vaccination with CD4 carrying TRBV19 or a virus carrying an epitope recognized by CD8 positive T cells, the number of TCR clones carrying TRBV19 is enhanced
Data Source
AI summary
Provided is an enhancer of number of TCR clones containing live lactic acid bacteria as an active ingredient. Provided is an enhancer of number of TCR clones, containing live lactic acid bacteria as an active ingredient, wherein after vaccination with CD4 carrying TRBV19 such as vaccination with IEV or a virus carrying an epitope recognized by CD8 positive T cells, the number of TCR clones carrying TRBV19 is enhanced.